Literature DB >> 24857207

[Monosomal karyotype among adult acute myeloid leukemia: clinical characteristic and prognostic analysis].

Ru Feng1, Hui Liu1, Naibai Chang1, Yun Fan1, Jiangtao Li1, Yeping Zhang1, Wei Chen1, Haifei Wang1, Yuan Tian1, Lei Pei1, Shangyong Ning1, Baoli Xing1, Xiaodong Xu1.   

Abstract

OBJECTIVE: To explore the clinical characteristics and prognostic value of monosomal karyotype (MK) patients in adult acute myeloid leukemia (AML).
METHODS: We retrospectively studied 45 patients of MK⁺ in newly-diagnosed adult AML in our center from Oct 2000 to Dec 2012. Clinical characteristics, cytogenetic data and prognostic features were analyzed in the cohort of MK⁺ patients.
RESULTS: MK was found in 45 patients (19.0%) of 237 newly-diagnosed adult AML with cytogenetic data available at diagnoses. Among these 45 cases, there were 28 male (62.2%) and 17 female (37.8%). Median age of MK⁺ patients at diagnose was 58(18-91) years old. The presence of -5(31.1%) and -7(17.8%) were the most common chromatid among MK⁺ AML patients. MK was much more prevalent among elderly patients. Among AML patients, the proportions of MK⁺ patients younger than 30, 30 to 59 and older than 60 years old groups were 11.5%, 17.7% and 22.4%, respectively. There was no difference between MK⁺ and MK⁻ patients in gender distribution (P=0.545). There was also no difference between MK⁺ and MK⁻ patients in the distribution of FAB castigation (P=0.239). Median survival of MK⁺ AML patients was 6.5 months. Cumulative 5-year overall survival (OS) of was 5.2%. Forty-three MK⁺ patients (43/45, 95.6%) also had a complex karyotype (CK). Two cases that did not meet the CK had not achieved complete remission (CR), and died within 6 months. There were 12 patients who were CK⁺ in 192 MK⁻ patients. The differences of OS and CR rates between MK⁺CK⁺ patients and MK⁻CK⁺ were statistically significant (P<0.05).
CONCLUSION: The increased detection rate of MK with age was associated with lower CR and OS in AML patients.

Entities:  

Mesh:

Year:  2014        PMID: 24857207     DOI: 10.3760/cma.j.issn.0253-2727.2014.05.004

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  3 in total

1.  Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.

Authors:  N Alam; E G Atenafu; J Kuruvilla; J Uhm; J H Lipton; H A Messner; D H Kim; M Seftel; V Gupta
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

2.  [Minimal residual disease level predicts outcomes in the non-favorable risk patients with acute myeloid leukemia].

Authors:  X Ren; T Zhao; J Wang; H H Zhu; H Jiang; J S Jia; S M Yang; B Jiang; D B Wang; X J Huang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

3.  [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].

Authors:  X Ren; T Zhao; J Wang; H H Zhu; H Jiang; J S Jia; S M Yang; B Jiang; D B Wang; X J Huang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.